First High-Quality Study to Explore A Carnivore-Style Diet in Managing Metabolic Health, WhichAffects Millions of AmericansOver one-third of U.S. adults – or 115.2 million Americans – are prediabetic, ...
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial Earlier detection of cancer offers an opportunity to ...
Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta–selective agonist in development for ...
Malaria control and elimination is threatened by the spread of insecticide resistance and behavioral adaptation of vectors. Whether mass administration of ivermectin, a broad-spectrum antiparasitic ...
An international, randomized, double-blind, placebo-controlled Phase III study—the largest of its kind for mpox—found that tecovirimat did not improve clinical outcomes for adults with clade II mpox ...
Thought LeadersAoife Hayes, Kevin O'Regan & Julie ScanlonClinical Trials Assitant, Operations Manager & Quality Assurance ManagerAtlantia Clinical Trials Food clinical trials may not be as familiar to ...
Remote clinical pharmacist impact on reducing total cost of care in Enhancing Oncology Model–enrolled oncology practices. Electronic patient-reported outcome-based weight management versus usual care ...
“Well, we don’t have as much evidence as we would like on steroid use during pregnancy,” the obstetrician warned my co-author, Natalia Emanuel, as she wrote a prescription for inhaled corticosteroids ...
The FDA is raising the bar for approval of CAR T-cell therapies in oncology. Under plans outlined by the FDA’s biologics chief Vinay Prasad, M.D., the agency will require developers of many CAR-Ts to ...
Gene Therapy Meets Regulatory Reality: The FDA–uniQure Clash Over a Promising Huntington’s Treatment
The FDA’s dispute with biotech firm uniQure over Huntington’s gene therapy highlights growing tensions between innovation, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results